Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells

収録刊行物

• Mol Pharmacol

  Mol Pharmacol 73 1290-1300, 2008